Pharmaceuticals

Tysabri (natalizumab) Market 2026–2030: Forecasting Business Opportunities Ahead

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the tysabri (natalizumab) market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Tysabri (natalizumab) Market size between 2026 and 2035?

The tysabri (natalizumab) market size has shown significant expansion in recent years. It is anticipated to increase from $2.66 million in 2025 to $2.87 million in 2026, exhibiting a compound annual growth rate (CAGR) of 8.1%. This historic growth can be ascribed to factors such as the rising prevalence of multiple sclerosis, the authorization of natalizumab therapy, its uptake by neurologists, the existing unmet need in aggressive MS cases, and the growth in infusion center availability.

The market size for tysabri (natalizumab) is anticipated to experience robust expansion over the coming years. It is projected to climb to $3.87 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period is attributable to several factors, including an increase in MS diagnosis rates, advancements in infusion infrastructure, enhanced risk mitigation programs, the rise of specialty neurology services, and support from long-term clinical outcomes. Prominent trends observed in the forecast period include the increasing utilization of monoclonal antibodies in MS treatment, a preference for high-efficacy disease-modifying therapies, the expansion of outpatient infusion care, refined safety and risk monitoring protocols, and a growing emphasis on managing progressive MS.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19942&type=smp

Which Drivers Are Impacting Market Performance In The Tysabri (natalizumab) Market?

The tysabri (natalizumab) market is projected to grow due to the increasing incidence of autoimmune disorders. These conditions involve the immune system erroneously attacking the body’s own cells, tissues, or organs, causing inflammation and damage that result in chronic ailments such as rheumatoid arthritis or multiple sclerosis, influenced by genetic and environmental factors. The rising prevalence of autoimmune disorders stems from genetic susceptibilities, environmental stimuli, and improved awareness and diagnostic methods, leading to more identified cases. Tysabri effectively manages autoimmune disorders by targeting specific immune cells, preventing inflammation and damage, which aids in treating conditions like multiple sclerosis and Crohn’s disease. For instance, in February 2024, Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, stated that by 2025, an estimated 562,378 Australians are expected to be living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the increased prevalence of autoimmune disorders is a key driver for the tysabri (natalizumab) market.

Which Segments Are Contributing To The Growth Of The Tysabri (natalizumab) Market?

The tysabri (natalizumab) market covered in this report is segmented –

1) By Clinical Indication: Multiple Sclerosis, Crohn’s Disease

2) By Patient Setting: Inpatient, Outpatient

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Opening Growth Opportunities In The Tysabri (natalizumab) Market?

Leading companies in the tysabri (natalizumab) market are focused on broadening treatment options with alternative solutions, such as biosimilars, to provide patients with more effective therapies that improve their quality of life and disease management. Biosimilars to Tysabri offer an economical choice for treating highly active relapsing-remitting multiple sclerosis, thereby increasing access to vital treatment, especially in underserved regions. For example, in January 2024, Sandoz Group AG, a pharmaceutical company from Switzerland, introduced Tyruko (natalizumab), which is the first and only biosimilar to Tysabri, for the treatment of adults experiencing highly active relapsing-remitting multiple sclerosis (RRMS). This launch reinforces Sandoz’s biosimilar portfolio and aims to enhance access to effective and affordable treatments for individuals living with multiple sclerosis.

Who Are The Core Companies Influencing Trends In The Tysabri (natalizumab) Market?

Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Tysabri (natalizumab) Market?

North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tysabri (natalizumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19942&type=smp

Browse Through More Reports Similar to the Global Tysabri (natalizumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Tylosin Market Report 2026

https://www.thebusinessresearchcompany.com/report/tylosin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795